Viking Therapeutics, Inc. $VKTX Shares Bought by Oppenheimer & Co. Inc.

Oppenheimer & Co. Inc. raised its position in shares of Viking Therapeutics, Inc. (NASDAQ:VKTX) by 25.5% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 183,583 shares of the biotechnology company’s stock after buying an additional 37,324 shares during the quarter. Oppenheimer & Co. Inc. owned about 0.15% of Viking Therapeutics worth $5,985,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. Ameritas Advisory Services LLC purchased a new stake in shares of Viking Therapeutics during the 2nd quarter worth approximately $32,000. Ballast Advisors LLC bought a new position in shares of Viking Therapeutics during the 1st quarter valued at approximately $33,000. Root Financial Partners LLC purchased a new position in shares of Viking Therapeutics in the third quarter valued at $34,000. Cassaday & Co Wealth Management LLC purchased a new position in shares of Viking Therapeutics in the first quarter valued at $50,000. Finally, Allworth Financial LP purchased a new position in shares of Viking Therapeutics in the second quarter valued at $53,000. Institutional investors own 76.03% of the company’s stock.

Viking Therapeutics Stock Up 1.9%

Shares of VKTX stock opened at $25.36 on Thursday. The firm has a market cap of $3.20 billion, a price-to-earnings ratio of -5.44 and a beta of 0.66. The company’s 50 day moving average is $30.84 and its 200 day moving average is $32.47. Viking Therapeutics, Inc. has a 52-week low of $23.82 and a 52-week high of $43.15.

Viking Therapeutics (NASDAQ:VKTX) last released its quarterly earnings results on Wednesday, October 28th. The biotechnology company reported ($1.55) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.06) by ($0.49). During the same period last year, the firm earned ($0.81) EPS. Analysts anticipate that Viking Therapeutics, Inc. will post -4.46 EPS for the current fiscal year.

Trending Headlines about Viking Therapeutics

Here are the key news stories impacting Viking Therapeutics this week:

• Positive Sentiment: Viking reported a strong quarter-end cash position of approximately $960 million, providing substantial funding for its clinical programs and reducing near-term financing risk. Viking Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
• Positive Sentiment: Development of VK2735 continues to advance: Phase 3 VANQUISH trials for the injectable formulation are progressing, Phase 3 SUNRISE trials for the oral formulation have begun, and Viking reported positive top-line results from a maintenance-dosing study. Viking Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
• Neutral Sentiment: The company said its Phase 1 single-ascending-dose study of amylin agonist VK3019 is nearing completion, offering a potential additional metabolic-drug catalyst but one that remains at an early development stage. Viking Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
• Negative Sentiment: Viking reported a third-quarter loss of $1.55 per share, wider than the $1.06 analyst consensus and compared with a $0.81 loss a year earlier. The company generated no revenue as it continued increasing spending on obesity-drug development. Viking Therapeutics falls on third quarter loss miss
• Negative Sentiment: CEO Brian Lian’s estimate that a VK2735 launch could still be about two and a half years away frustrated retail investors, highlighting the extended timeline before the company may generate commercial revenue. VKTX Stock Slides Overnight After Q3 Loss

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on VKTX shares. Wall Street Zen cut shares of Viking Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Sunday, October 4th. Morgan Stanley reiterated an “overweight” rating on shares of Viking Therapeutics in a research report on Tuesday, September 22nd. Zacks Research raised shares of Viking Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Tuesday, August 18th. Canaccord Genuity Group dropped their price objective on shares of Viking Therapeutics from $114.00 to $106.00 and set a “buy” rating for the company in a research note on Tuesday, October 20th. Finally, HC Wainwright restated a “buy” rating on shares of Viking Therapeutics in a report on Tuesday, September 22nd. Two research analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $98.10.

Viking Therapeutics Profile

Viking Therapeutics, Inc is a clinical-stage biopharmaceutical company headquartered in San Diego, California. Founded in 2012, the company develops therapies for metabolic and endocrine disorders, with a focus on conditions involving obesity, nonalcoholic steatohepatitis (NASH), and other liver and lipid disorders.

Viking’s lead program is VK2735, an investigational dual GLP-1/GIP receptor agonist being developed in injectable and oral formulations for obesity and related metabolic conditions.